
Sign up to save your podcasts
Or
Adam, Elaine, and Allison discuss the Trump administration’s plan for huge job cuts and a restructuring of the country’s top health care agencies, the approval of the first drug to treat a devastating rare disease, and the bankruptcy of 23andMe. Then, they bring on the chief executive of startup Altis Labs to discuss new data from a study they conducted with AstraZeneca on an AI tool for cancer drug development.
4.5
304304 ratings
Adam, Elaine, and Allison discuss the Trump administration’s plan for huge job cuts and a restructuring of the country’s top health care agencies, the approval of the first drug to treat a devastating rare disease, and the bankruptcy of 23andMe. Then, they bring on the chief executive of startup Altis Labs to discuss new data from a study they conducted with AstraZeneca on an AI tool for cancer drug development.
30,845 Listeners
1,040 Listeners
1,789 Listeners
478 Listeners
122 Listeners
84 Listeners
5,942 Listeners
391 Listeners
59 Listeners
29 Listeners
5,462 Listeners
147 Listeners
18 Listeners
51 Listeners
371 Listeners